

List of Tables

| | |
|---|-----|
| Table 1: Current therapies for the treatment of RA..... | 10 |
| Table 2: Immunotherapy for the treatment of cancer..... | 13 |
| Table 3: Small molecule inhibitors for the treatment of cancer..... | 14 |
| Table 4: PI3K enzyme classification..... | 18 |
| Table 5: PI3K Inhibitors in clinical development..... | 23 |
| Table 6: <i>In vitro</i> PI3K δ inhibitory activity data of Imidazo-quinoline derivatives with Modifications at R ₁ position (Set-1) | 79 |
| Table 7: Influence of modification at R ₂ position of quinoline moiety on PI3K δ Inhibitory activity and isoform selectivity (Set-2) | 80 |
| Table 8: Isoform selectivity of compounds against PI3K (α , β , γ , and δ) and mTOR activities..... | 82 |
| Table 9: Pharmacokinetic study parameters of 9c , 10h and Dactolisib in C57 mice..... | 84 |
| Table 10: Relative organ weights (%) after 14 days repeat dose treatment with compound 10h | 86 |
| Table 11: Hematological parameters and serum chemistry of compound 10h | 87 |
| Table 12: <i>In vitro</i> PI3K δ inhibitory activity data Benzofuran pyrazolo pyrimidine derivatives..... | 126 |
| Table 13: Isoform selectivity of compounds against PI3K (α , β , γ , and δ) and mTOR activities..... | 128 |
| Table 14: <i>In vitro</i> PI3K δ inhibitory activity data of 2,4-disubstituted quinoline pyrazolo pyrimidine derivatives..... | 156 |